Agenus, Inc.

As of November 8, 2022, Agenus, Inc. is considered overvalued and has a risky valuation grade due to troubling financial ratios and significant underperformance compared to the S&P 500, with a 3-year return of -90.09% and a 5-year return of -95.52%.

As of November 8, 2022, Agenus, Inc. is considered undervalued and risky due to negative financial metrics, including a Price to Book Value of -0.48 and a year-to-date return of 75.18%, despite a one-year decline of 67.03% compared to the S&P 500's 10.26% return.

As of June 20, 2025, Agenus, Inc. shows a mildly bullish trend supported by a bullish weekly MACD and daily moving averages, though caution is advised due to mildly bearish monthly Bollinger Bands and mixed signals from the KST.

As of March 2022, the management team of Agenus, Inc. includes Dr. Garo Armen (Chairman, CEO, Co-Founder), Mr. Timothy Wright (Lead Independent Director), Mr. Paul Clark, Ms. Susan Hirsch, Mr. Brian Corvese, and Dr. Allison Jeynes-Ellis (all Directors).

Agenus, Inc. is an immuno-oncology company developing therapies to harness the immune system against cancer, with a market cap of $131.05 million and recent net sales of $24 million. The company reported a net loss of $26 million for the quarter ending March 2025.

As of Jun 18, Agenus, Inc. has a market capitalization of 131.05 million, with net sales of 99.53 million and a net profit of -195.19 million over the last four quarters. Shareholder's funds are reported at -326.38 million, and total assets amount to 226.27 million.